Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis.
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
von Recklinghausen neurofibromatosis (NF1) is a common hereditary disorder characterized by neural crest-derived tumors, particularly benign neurofibromas whose malignant transformation to neurofibrosarcomas can be fatal. The NF1 gene has been mapped to a small region of chromosome 17q, but neither the nature of the primary defect nor the mechanisms involved in tumor progression are understood. We have tested whether NF1 might be caused by the inactivation of a tumor suppressor gene on 17q, analogous to that on chromosome 22 in NF2, by searching for deletions of chromosome 17 in NF1-derived tumor specimens. Both neurofibrosarcomas from patients with "atypical" NF and 5 of 6 neurofibrosarcomas from NF1 patients displayed loss of alleles for polymorphic DNA markers on chromosome 17. However, the common region of deletion was on 17p and did not include the NF1 region of 17q. Since no loss of markers on chromosome 17 was observed in any of 30 benign tumors from NF1 patients, the 17p deletions seen in neurofibrosarcomas are probably associated with tumor progression and/or malignancy. This region contains a candidate gene for tumor progression, p53, which has recently been implicated in the progression of a broad array of human cancers. In a preliminary search for p53 aberrations by direct sequencing of polymerase chain reaction-amplified DNA from 7 neurofibrosarcomas, 2 tumors that contained point mutations in exon 4 of the p53 gene were found, suggesting a role for this gene in at least some neurofibrosarcomas. Thus the formation of malignant neurofibrosarcomas may result from several independent genetic events including mutation of the NF1 gene, whose mechanism of tumorigenesis remains uncertain, and subsequent loss of a "tumor suppressor" gene on 17p, most likely p53.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in the p53 gene occur in diverse human tumour types
Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hosteller, R., Cleary, K., Signer, S. H., Davidson, N., Baylin, S., Devilee, P., et al. (1989) · Nature · doi:10.1038/342705a0 · Cited by 2,733
Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,066
The p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987
Von Recklinghausen Neurofibromatosis
Riccardi, V. M. (1981) · New England Journal of Medicine · doi:10.1056/nejm198112313052704 · Cited by 1,344
Self-citationp53: A Frequent Target for Genetic Abnormalities in Lung Cancer
Takahashi, T., Nau, M. M., Chiba, I., Birrer, M. J., Rosenberg, R. K., Vinocour, M., Levitt, M., Pass, H., Gazdar, A. F., & Minna, J. D. (1989) · Science · doi:10.1126/science.2554494 · Cited by 1,197
(1988) · PubMed · Cited by 1,161
Gene for von Recklinghausen Neurofibromatosis Is in the Pericentromeric Region of Chromosome 17
Barker, D., Wright, E., Nguyen, K., Cannon, L., Fain, P., Goldgar, D., Bishop, D. T., Carey, J., Baty, B., Kivlin, J., et al. (1987) · Science · doi:10.1126/science.3107130 · Cited by 695
Long-Term Follow-up of von Recklinghausen Neurofibromatosis
Sørensen, S. A., Mulvihill, J. J., & Nielsen, A. (1986) · New England Journal of Medicine · doi:10.1056/nejm198604173141603 · Cited by 617
Hinds, P., Finlay, C., & Levine, A. J. (1989) · Journal of Virology · doi:10.1128/jvi.63.2.739-746.1989 · Cited by 577
Characterization of the human p53 gene.
Lamb, P., & Crawford, L. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.5.1379 · Cited by 327
Cited by
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Self-citationWeinberg, R. A. (1991) · Science · doi:10.1126/science.1659741 · Cited by 1,756
Cawthon, R. M., Weiss, R., Xu, G., Viskochil, D., Culver, M., Stevens, J., Robertson, M., Dunn, D., Gesteland, R., O'Connell, P., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90253-b · Cited by 1,094
Identification of p53 as a Sequence-Specific DNA-Binding Protein
Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., & Vogelstein, B. (1991) · Science · doi:10.1126/science.2047879 · Cited by 1,085
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
“214,215 TP53 mutations are a hallmark of an inherited cancer susceptibility syndrome known as Li-Fraumeni.”
BackgroundOncogenic forms of p53 inhibit p53-regulated gene expression
Kern, S., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1589764 · Cited by 940
Identification of p53 Gene Mutations in Bladder Cancers and Urine Samples
Sidransky, D., Von Eschenbach, A., Tsai, Y. C., Jones, P., Summerhayes, I., Marshall, F., Paul, M., Green, P., Hamilton, S. R., Frost, P., et al. (1991) · Science · doi:10.1126/science.2024123 · Cited by 875
Antioncogenes and human cancer.
Knudson, A. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.10914 · Cited by 762
Marshall, C. J. (1991) · Cell · doi:10.1016/0092-8674(91)90641-b · Cited by 751
Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients
Basu, T. N., Gutmann, D. H., Fletcher, J. A., Glover, T. W., Collins, F. S., & Downward, J. (1992) · Nature · doi:10.1038/356713a0 · Cited by 668
Lee, W., Teckie, S., Wiesner, T., Ran, L., Prieto Granada, C. N., Lin, M., Zhu, S., Cao, Z., Liang, Y., Sboner, A., et al. (2014) · Nature Genetics · doi:10.1038/ng.3095 · Cited by 619
NF1 Tumor Suppressor Gene Function
Cichowski, K., & Jacks, T. (2001) · Cell · doi:10.1016/s0092-8674(01)00245-8 · Cited by 601
tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors
Berghmans, S., Murphey, R. D., Wienholds, E., Neuberg, D., Kutok, J. L., Fletcher, C. D. M., Morris, J. P., Liu, T. X., Schulte-Merker, S., Kanki, J. P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406252102 · Cited by 597
Bollag, G., Clapp, D. W., Shih, S., Adler, F., Zhang, Y. Y., Thompson, P., Lange, B. J., Freedman, M. H., McCormick, F., Jacks, T., et al. (1996) · Nature Genetics · doi:10.1038/ng0296-144 · Cited by 589
TP53 tumor suppressor gene: A model for investigating human mutagenesis
Fromentel, C. C. D., & Soussi, T. (1992) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.2870040102 · Cited by 574
A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor
Ratner, N., & Miller, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3911 · Cited by 493
Mouse Models of Tumor Development in Neurofibromatosis Type 1
Cichowski, K., Shih, T. S., Schmitt, E., Santiago, S., Reilly, K., McLaughlin, M. E., Bronson, R. T., & Jacks, T. (1999) · Science · doi:10.1126/science.286.5447.2172 · Cited by 467
Shannon, K. M., O'Connell, P., Martin, G. A., Paderanga, D., Olson, K., Dinndorf, P., & McCormick, F. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300903 · Cited by 444
Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects
Reilly, K. M., Loisel, D. A., Bronson, R. T., McLaughlin, M. E., & Jacks, T. (2000) · Nature Genetics · doi:10.1038/79075 · Cited by 425
Legius, E., Marchuk, D. A., Collins, F. S., & Glover, T. W. (1993) · Nature Genetics · doi:10.1038/ng0293-122 · Cited by 391
cDNA cloning of the type 1 neurofibromatosis gene: Complete sequence of the NF1 gene product
Marchuk, D. A., Saulino, A. M., Tavakkol, R., Swaroop, M., Wallace, M. R., Andersen, L. B., Mitchell, A. L., Gutmann, D. H., Boguski, M., & Collins, F. S. (1991) · Genomics · doi:10.1016/0888-7543(91)90017-9 · Cited by 389
Molecular genetics of neurofibromatosis type 1 (NF1).
Shen, M. H., Harper, P. S., & Upadhyaya, M. (1996) · Journal of Medical Genetics · doi:10.1136/jmg.33.1.2 · Cited by 377
Mouse Tumor Model for Neurofibromatosis Type 1
Vogel, K. S., Klesse, L. J., Velasco-Miguel, S., Meyers, K., Rushing, E. J., & Parada, L. F. (1999) · Science · doi:10.1126/science.286.5447.2176 · Cited by 372
Jones, P. A. (2002) · Oncogene · doi:10.1038/sj.onc.1205597 · Cited by 321
The Molecular and Genetic Basis of Neurological Tumours
Zhu, Y., & Parada, L. F. (2002) · Nature Reviews Cancer · doi:10.1038/nrc866 · Cited by 309
Side, L., Taylor, B., Cayouette, M., Conner, E., Thompson, P., Luce, M., & Shannon, K. (1997) · New England Journal of Medicine · doi:10.1056/nejm199706123362404 · Cited by 295
Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study
Stiller, C., Chessells, J., & Fitchett, M. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.431 · Cited by 287
Nielsen, G. P., Stemmer-Rachamimov, A. O., Ino, Y., Møller, M. B., Rosenberg, A. E., & Louis, D. N. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65507-1 · Cited by 266
Jaros, E., Perry, R., Adam, L., Kelly, P., Crawford, P., Kalbag, R., Mendelow, A., Sengupta, R., & Pearson, A. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.273 · Cited by 264
Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors
Beert, E., Brems, H., Daniëls, B., De Wever, I., Van Calenbergh, F., Schoenaers, J., Debiec‐Rychter, M., Gevaert, O., De Raedt, T., Van Den Bruel, A., et al. (2011) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20921 · Cited by 255
Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene
Colman, S. D., Williams, C. A., & Wallace, M. R. (1995) · Nature Genetics · doi:10.1038/ng0995-90 · Cited by 252
Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis
Woodruff, J. M. (1999) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19990326)89:1<23::aid-ajmg6>3.0.co;2-# · Cited by 229
Miller, S. J., Rangwala, F., Williams, J., Ackerman, P., Kong, S., Jegga, A. G., Kaiser, S., Aronow, B. J., Frahm, S., Kluwe, L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3330 · Cited by 211
Loss of heterozygosity in human skin
Happle, R. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70042-3 · Cited by 205
Kourea, H. P., Orlow, I., Scheithauer, B. W., Cordon-Cardo, C., & Woodruff, J. M. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65504-6 · Cited by 170
Lau, N., Feldkamp, M. M., Roncari, L., Loehr, A. H., Shannon, P., Gutmann, D. H., & Guha, A. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.9.759 · Cited by 167
“Our data demonstrate loss of neurofibromin in an NF1-associated astrocytoma without LOH at the p53 locus, differentiating NF1-associated astrocytomas from sporadic astrocytomas and from NF1associated MPNST (34, 35).”
BackgroundInfluentialThe Loss of Nf1 Transiently Promotes Self-Renewal but Not Tumorigenesis by Neural Crest Stem Cells
Joseph, N. M., Mosher, J. T., Buchstaller, J., Snider, P., McKeever, P. E., Lim, M., Conway, S. J., Parada, L. F., Zhu, Y., & Morrison, S. J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.003 · Cited by 167
Neurofibromatosis type 1-associated tumours: Their somatic mutational spectrum and pathogenesis
Spyk, S., Thomas, N., Cooper, D. N., & Upadhyaya, M. (2011) · Human Genomics · doi:10.1186/1479-7364-5-6-623 · Cited by 164
“2(19) and contains 61 exons.(3,20) Neurofibromin, the 327 kDa protein encoded by the NF1 gene, is translated from a 12 kb messenger mRNA transcript, and has a number of alternative isoforms (reviewed by Upadhyaya(25)).”
BackgroundInfluentialNeurofibromatosis: Past, Present, and Future
Riccardi, V. M. (1991) · New England Journal of Medicine · doi:10.1056/nejm199105023241812 · Cited by 159
Self-citationMenendez, D., Nguyen, T.-A., Freudenberg, J. M., Mathew, V. J., Anderson, C. W., Jothi, R., & Resnick, M. A. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt504 · Cited by 154
Zhang, Y.-Y., Vik, T. A., Ryder, J. W., Srour, E. F., Jacks, T., Shannon, K., & Wade Clapp, D. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.11.1893 · Cited by 150
Lévy, P., Ripoche, H., Laurendeau, I., Lazar, V., Ortonne, N., Parfait, B., Leroy, K., Wechsler, J., Salmon, I., Wolkenstein, P., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0182 · Cited by 53
Metadata
- Authors
- Menon, A. G., Anderson, K. M., Riccardi, V. M., Chung, R. Y., Whaley, J. M., Yandell, D. W., Farmer, G. E., Freiman, R. N., Lee, J. K., & Li, F. P.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1990-07
- Volume
- 87
- Issue
- 14
- Pages
- 5435-5439
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2133927414
- Cited by
- 395
- References
- 18
- FWCI
- 25.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.